cisplatin,gemcitabine,nivolumab
bms
['mibc', 'nivolumab', 'cisplatin', 'hcrn,gu,16-257', '#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)', 'nivo', 'gemcitabine', 'bladder']
rapid bladder abstracts #gu23 kicking off with #gu16257 by : mibc t2-t4an0 pts got 4 cycles gem/cis + nivolumab -&gt; those w cr -&gt; cystectomy vs no cystectomy (with adjuvant nivolumab) 43% pts had clinical cr identified pts who can maybe avoid cystectomy 
GU Oncologist | 🇨🇦 GU & NOLA Heme/Onc Alumni | Interested in GU, Immuno Onc & Med Ed | @ASCO Featured Voice | @TwoOncDocs podcast